In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kate Rawson

Kate Rawson is a Contributing Editor at Prevision Policy. She was a Senior Editor at The RPM Report and reporter and editor at The Pink Sheet where she covered drug regulation and reimbursement issues. During her ten-year tenure at FDC Reports, she helped launch The Pink Sheet DAILY, and also served as Managing Editor of The Rose Sheet, which covers regulatory and business news of the cosmetics industry.
Advertisement
Set Alert for Articles By Kate Rawson

Latest From Kate Rawson

'Project Orbis' Oncology Pilot Eventually Will Target 'Major Impact' Applications

But US FDA is starting small, OCE Director Pazdur says. Program will hand-select approve high-priority oncology treatments that have to potential to change the standard of care.

Cancer Drug Review

Mitochondrial Disease Workshop Shows US FDA Commitment To First Approvals

First FDA-hosted workshop on rare family of mitochondrial diseases offers plenty of opportunities to talk challenges in R&D – and identify some solutions.

United States Clinical Trials

ICER Reviews Duchenne: Exondys 51 Lacks Net Health Benefit; Emflaza Fairs Better

High price tag, thin evidence of clinical efficacy for Exondys 51 result in low score from ICER, but a re-do is almost certain when confirmatory data on eteplirsen are released.

Reimbursement Neurology

Congress’ Next Steps On REMS Abuses: Will Improving FDA-FTC Communication Help?

US FDA has seen little success in ending gaming of the patent process by brand name manufacturers. One problem: the agency’s referrals to FTC on anti-competitive cases appear go into a black box.

Generic Drugs Legal Issues

First Amendment Challenge To DTC Rule Unlikely From Industry; For Now, It Is 'Comply With Context'

DTC rule is a good fight to lose: it is a high-profile response to pricing, but will have a low impact – and is certainly a less painful solution than many of the alternatives.
Advertising, Marketing & Sales Pricing Debate

FDA Finalizes Comparative Safety, Efficacy Requirement For New Opioids

New opioids will need to provide a “significant advantage” over approved products under new requirements that treat opioids “differently” from other drug classes, outgoing Commissioner Gottlieb says.
Neurology Drug Review
See All
Advertisement
UsernamePublicRestriction

Register